ClinicalTrials.gg
TerminatedNCT04449588Updated May 22, 2024

Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS

A Phase 2/3 interventional study of BDB-001 Injection and Conventional treatment in COVID-19 Pneumonia, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Terminated at 12 sites in 5 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.

Enrollment
65th of 254
369 · median 132
Started
2020
with 204 others
Phase 2/3
25 of 401
1 open now
Registered
119th of 401
by date

Among the 401 studies in COVID-19 with a site in Spain, this one is the 65th largest by enrollment of the 254 interventional ones that give a count, is one of 205 that started in 2020, is one of 25 in phase 2/3, and was the 119th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Open to participants now

25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in COVID-19 with a site in Spain, or all of them as a file.
02

Study summary

This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001 injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome. Patients will be randomized to two treatment arms (Arm A: Conventional treatment + BDB-001; Arm B: Conventional treatment alone).

03

Conditions studied

  • COVID-19 Pneumonia

Keywords

  • COVID-19
  • Severe Pneumonia
  • ALI/ARDS
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old ≤ age ≤ 80 years old, both men or women.
  2. Confirmed SARS-CoV-2 infection, and meet at least one of the following criteria:

    Confirmed severe COVID-19 in no more than 5 days who meets any of the following criteria:

    1. Respiratory distress, RR ≥ 30 times/min
    2. Finger oxygen saturation (SpO2) ≤93% in resting state(room air)
    3. Arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ≤ 300 mmHg (1 mmHg = 0.133kpa) in supine position
    4. Pulmonary imaging shows lesion progression > 50% within 24-48 hours.

    Symptoms,signs or chest imaging indicates ALI/ARDS;

  3. Requiring a mask oxygen therapy,high-flow nasal cannula oxygen therapy(HFNC).
  4. The form signed.

Exclusion criteria

Exclusion Criteria:

Subject who meets any of the following criteria will be excluded from the trial:

  1. Subjects already progressed into critically severe COVID-19 Critical severe standards refer to FDA guidelines,as shown in Appendix 4 or sepsis and sepsis shock.
  2. Concomitant with the following situation:severe lung disease such as (moderate to severe type), lung cancers, active tuberculosis; severe cardiovascular and cerebrovascular disease: unstable angina pectoris, myocardial infarction, postcardiac surgery, cardiac function ≥ grade 3 ( Classification), or had undergone heart surgery within 6 months before randomization; severe liver diseases (e.g. score ≥ grade C); severe kidney diseases, such as renal insufficiency ( ≤ 15 mL/min/1.73m\^2); immune deficiencies or immune-related diseases : including organ or bone marrow transplantation, some diseases, IgG4-related diseases, allergic alveolitis, vasculitis; .
  3. Subjects on current treatment with a complement inhibitor such as eculizumab within 1 month before randomization.
  4. Subjects with history to any ingredient contained in the drug.
  5. A subject has used the following drugs within 2 weeks prior to screening procedures:

    • Calcineurin inhibitors (e.g., ciclosporin, tacrolimus, etc.)
    • Proliferation inhibitors (e.g., everolimus, sirolimus, etc.)
    • Anti-metabolic drugs (e.g., mycophenolate mofetil, mycophenolate, purine sulphate, etc.)
    • Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF)/recombinant human granulocyte colony stimulating factor (rhG-CSF)
  6. Pregnant or lactating woman.
  7. Subjects who have participated in other interventional clinical trials in the last 3 months or during this trial.
  8. Any other circumstances that the investigator considers inappropriate for the participation in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
369 participants (actual)

Study arms

  • Experimental
    Treatment group

    Drug: BDB-001 Injection

  • Experimental
    Control group

    Other: Conventional treatment

Interventions

  • BDB-001 Injection+Conventional treatment

  • OtherConventional treatment

    Conventional treatment only. Local guidelines should be integrated to choose the best supportive care.

06

What researchers measure

Primary outcomes

  1. Time to recovery of peripheral capillary oxygen saturation (SpO2) from baseline

    Time frame: Baseline to Day 28

Secondary outcomes

  1. 28-day all-cause mortality rate

    Time frame: Baseline to Day 28

  2. Percentage of patients who progress to critical severe

    Time frame: Baseline to Day 28

  3. Percentage of subjects achieving recovery in SpO2

    Time frame: Baseline to Day 28

  4. Mean change of PaO2/FiO2

    Time frame: Baseline to Day 28

  5. Mechanical ventilation time

    Time frame: Baseline to Day 28

  6. Time of oxygen therapy

    Time frame: Baseline to Day 28

  7. Change in inflammation indicators (CRP or IL-6 etc.) from baseline

    Time frame: Baseline to Day 28

  8. Improvement in body temperature

    Time frame: Baseline to Day 28

  9. Mean change from baseline in the clinical improvement based on ordinal scale recommended by the WHO R&D Blueprint during treatment period

    Time frame: Baseline to Day 28

  10. Improvement at D3, 7, 11 & D14 based on ordinal scale recommended by the WHO R&D Blueprint during treatment period

    Time frame: Baseline,Day 3,Day 7,Day 11,Day 14

  11. Time to get categories 1 to 4 in the 8-points ordinal scale

    Time frame: Baseline to Day 28

  12. Time to attain an improvement of 1 point on the ordinal scale

    Time frame: Baseline to Day 28

07

Study locations

12 sites
  • Asgar Ali Hospital
    Dhaka, Bangladesh
  • Bangladesh Specialized Hospital
    Dhaka, Bangladesh
  • Southwest Hospital Chongqing
    Chongqing, Chongqing 400038, China
  • Noble Hospital Pvt Ltd
    Nagpur, India
  • Government Medical College and Hospital
    Pune, India
  • RSUD Cengkareng(Cengkareng General Hospital)
    Jakarta, Jakrata 11730, Indonesia
  • RSUD Pasar Minggu(Pasar Minggu General Hospital)
    Jakarta, 12550, Indonesia
  • RSUP Persahabatan(Persahabatan General Hospital)
    Jakarta, 13230, Indonesia
  • Hospital Universitario 12 De Octubre
    Madrid, Spain
  • Hospital Universitario Clínico San Carlos
    Madrid, Spain
  • Hospital Universitario de la Princesa
    Madrid, Spain
  • Hospital Universitario Fundación Díaz
    Madrid, Spain
08

References and documents

Publications

  • Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-52. doi: 10.1146/annurev.immunol.23.021704.115835. PubMed 15771587 ↗
  • Wood AJT, Vassallo A, Summers C, Chilvers ER, Conway-Morris A. C5a anaphylatoxin and its role in critical illness-induced organ dysfunction. Eur J Clin Invest. 2018 Dec;48(12):e13028. doi: 10.1111/eci.13028. Epub 2018 Oct 15. PubMed 30229880 ↗
  • Wang R, Xiao H, Guo R, Li Y, Shen B. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infect. 2015 May;4(5):e28. doi: 10.1038/emi.2015.28. Epub 2015 May 6. PubMed 26060601 ↗
  • Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, Guo Y, Kou Z, Yu H, Li J, Wang R, Li Y, Schneider C, Habel M, Riedemann NC, Du L, Jiang S, Guo R, Zhou Y. Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis. 2015 Feb 15;60(4):586-95. doi: 10.1093/cid/ciu887. Epub 2014 Nov 27. PubMed 25433014 ↗
  • Sun S, Zhao G, Liu C, Wu X, Guo Y, Yu H, Song H, Du L, Jiang S, Guo R, Tomlinson S, Zhou Y. Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection. Am J Respir Cell Mol Biol. 2013 Aug;49(2):221-30. doi: 10.1165/rcmb.2012-0428OC. PubMed 23526211 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Mar 2024, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Jun 29, 2020
StartActual
Jul 23, 2020
Primary completionActual
Mar 26, 2024
CompletionActual
Mar 26, 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04449588
Collaborators
Beijing Defengrui Biotechnology Co. Ltd
Responsible party
Sponsor
First posted
Jun 29, 2020
Start date
Jul 23, 2020
Primary completion
Mar 26, 2024
Completion
Mar 26, 2024
Last update
May 22, 2024

Study contacts

Qing Mao, Ph.D
principal investigator · Southwest Hospital of Chongqing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BDB001

Start the discussion